close

Agreements

Date: 2011-02-07

Type of information: R&D agreement

Compound: drugs based on the inhibition of the dengue NS3 protease activity

Company: Medivir (Sweden) Janssen Pharmaceutica, a J&J company (USA)

Therapeutic area: Infectious diseases

Type agreement:

R&D

development

commercialisation

Action mechanism:

inhibition of the dengue NS3 protease

Disease: dengue fever

Details:

Medivir has signed a collaboration agreement with Janssen Pharmaceutica N.V. (Janssen) for the discovery and development of drugs for the prophylaxis and treatment of dengue virus infection. Utilising both companies’ core competences in the discovery and development of protease inhibitors, Medivir and Janssen will initiate an R&D program to co-develop drugs based on the inhibition of the dengue NS3 protease activity. The terms of the agreement govern the discovery, clinical development and commercialisation of any drugs developed under the agreement. Depending on the level of funding through pre-specified decision points, each party has the option to take products discovered through the research program forward through development and on to commercialisation.

Financial terms:

Both parties will contribute equal resources to the research program and Medivir has an option to continue to contribute equal funding for the non-clinical and clinical development stages. If both parties remain in the collaboration until product approval, Janssen will be responsible for commercialization. Medivir will receive pre-agreed royalties on net sales of future products that reflect its contribution to the development of products.

Latest news:

Is general: Yes